by Anna Megdell, University of Michigan Profiling of metabolite utilization in PDA cells identifies uridine. Credit: Nature (2023). DOI: 10.1038/s41586-023-06073-w Researchers at the University of Michigan Rogel Cancer Center have discovered a new nutrient source that pancreatic cancer cells use to grow. The molecule, uridine, offers insight into both biochemical processes and possible therapeutic pathways. The findings, published in...
16 MAY 2023 5:50 PM BY MITCH LESLIE Drugs that prevent new blood vessel growth may make tumors more vulnerable to checkpoint inhibitors. ELLA MARU STUDIO/SCIENCE SOURCE Patients with a type of liver cancer known as hepatocellular carcinoma (HCC) often face an anxious wait after their tumor is removed. In up to half of these...
by Nancy Fliesler, Children’s Hospital Boston Senescence inducer CuSO4, which causes ER stress, activates NKp46- and NKG2D-dependent NK killing, but 4-PBA, which induces senescence without ER stress, does not. a, Representative flow cytometry histograms of β-galactosidase activity (SA-βgal) (left) and MFI of 3 samples (right) of KP that were untreated (UT) or treated with CuSO4 or 4-PBA....
by Homa Shalchi, Baylor College of Medicine Engineered p16 epimutation recapitulates key features of age-associated epigenetic silencing. A p16 DNA methylation profiles in cis-MEF following serial passaging (p). A schematic of the p16 promoter of the cis-element knock-in allele with the CpG maps is shown. B Kinetics of p16 promoter methylation and mRNA expression in ctr-MEF and cis-MEF. Methylation levels were averaged from CpGs from − 814 bp to − 589 bp relative to the TSS....
by Swedish Research Council Graphical abstract. Credit: Cancer Cell (2023). DOI: 10.1016/j.ccell.2023.04.010 Researchers from Uppsala University have developed a method that helps immune cells exit from blood vessels into a tumor to kill cancer cells. The goal is to improve treatment of aggressive brain tumors. The study has been published in the journal Cancer Cell. Glioblastoma is an aggressive brain tumor that...
By Michael Irving May 09, 2023 Scientists have discovered a new cause of cancer – a mutation in a specific gene that interferes with a cellular cleanup process Depositphotos Cancer can be the end result of a wide range of things that go wrong, and understanding how is key to prevention and treatment. Now, scientists...
by University of Pittsburgh Universal adaptor SNAP-CAR and SNAP-synNotch receptor function. a A benzylguanine motif (BG) is chemically conjugated to an antibody using a benzylguanine NHS ester. The BG-antibody conjugate then covalently binds to the extracellular SNAPtag enzyme through a self-labeling reaction. b SNAPtag receptors enable the targeting of multiple different antigens using the same receptor...
by Maynooth University Credit: CC0 Public Domain Maynooth University’s Kathleen Londsdale Institute for Human Health Research has just published research into the benefits of the popular obesity treatment drug, GLP-1. Previous research has found that people with obesity are at a greater risk of developing cancer, in part due to their anticancer immune cells—better known as the ‘Natural Killer (NK)’ cell—being rendered...
by Justin Jackson, Medical Xpress Experimental workflow. a, Schematic of study workflow. In human participants with dominant hemisphere gliomas, we applied subcortical high density electrocorticography during audiovisual speech initiation to assess tumor intrinsic neuronal circuit dynamics. Focusing on glioblastoma, we then assessed long-range functional connectivity using magnetoencephalography (MEG) imaginary coherence. b, Extra-operative language assessments were...
by Elizabeth Chapin, University of Kentucky Succinate levels are elevated during EMT. (A) Expression of EMT markers was assessed by western blot in control, Snail1- and Twist1-expressing HMLE cells. (B) SIRM analysis showed the differential accumulation of metabolites in control and Twist1-expressing HMLE cells. (C) Quantification of succinate levels in control and Twist1-expressing HMLE cells with...
